Sepiapterin (2) – Sephience®

Hyperphenylalaninaemia associated with phenylketonuria

Characteristics

Start date 15.11.2026
Resolution 05.05.2027 – active procedure
INN Sepiapterin
Brand name Sephience®
Pharm. company PTC Therapeutics International Limited
G-BA Procedure ID D-1395
Therapeutic area Metabolic diseases
Reason for procedure Reassessment: Loss of orphan status

Associated procedures

Sepiapterin (2) Sephience® PTC Therapeutics International Limited Metabolic diseases Hyperphenylalaninaemia associated with phenylketonuria n.d. active procedure
Sepiapterin (1) Sephience® PTC Therapeutics International Limited Metabolic diseases Hyperphenylalaninaemia in phenylketonuria 4,700–6,800 100% Hint for non-quantifiable additional benefit Orphan


<< List of all resolutions